Alvotech and bioventure announce approval of avt02 (adalimumab) in egypt

Alvotech (nasdaq: alvo) and bioventure, a wholly owned subsidiary of globalone healthcare holding llc, today announced that the egyptian drug authority (eda) has approved the manufacturing and distribution of avt02 (adalimumab) a biosimilar for humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name adalimumab-eva™.
ALVO Ratings Summary
ALVO Quant Ranking